B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $85 from $96 and keeps a Buy rating on the shares. The company’s Q1 earnings release lacked material updates, the analyst tells investors in a research note. The firm updated Viking’s model post the quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating
- Viking Therapeutics Advances Clinical Pipeline in Q1 2025
- Promising Developments and Financial Stability Underpin Buy Rating for Viking Therapeutics
- Viking Therapeutics reports Q1 EPS (41c), consensus (31c)
- Viking Therapeutics options imply 8.5% move in share price post-earnings